Exosomal miRNA Biomarker Panel for Pancreatic Ductal Adenocarcinoma Detection in Patient Plasma: A Pilot Study

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is rapidly becoming one of the leading causes of cancer-related deaths in the United States, and with its high mortality rate, there is a pressing need to develop sensitive and robust methods for detection. Exosomal biomarker panels provide a promising avenue for PDAC screening since exosomes are highly stable and easily harvested from body fluids. PDAC-associated miRNAs packaged within these exosomes could be used as diagnostic markers. We analyzed a series of 18 candidate miRNAs via RT-qPCR to identify the differentially expressed miRNAs (p < 0.05, t-test) between plasma exosomes harvested from PDAC patients and control patients. From this analysis, we propose a four-marker panel consisting of miR-93-5p, miR-339-3p, miR-425-5p, and miR-425-3p with an area under the curve (AUC) of the receiver operator characteristic curve (ROC) of 0.885 with a sensitivity of 80% and a specificity of 94.7%, which is comparable to the CA19-9 standard PDAC marker diagnostic.

Plasma miRNA expression in patients with genetically confirmed multiple endocrine neoplasia type 1 syndrome and its phenocopies

“…были отобраны четыре микроРНК: miR-93-5p, miR-339-3p, miR-425-5p и miR-425-3p, различно экспрессирующиеся в плазме крови пациентов с аденокарциномой протоков поджелудочной железы по сравнению с контролем, с целью создания панели для диагностики рака протоков поджелудочной железы. Панель из этих четырех микроРНК имела площадь под кривой 0,885 с чувствительностью 80% и специфичностью 94,7%, что сопоставимо со стандартной маркерной диагностикой CA19-9 [ 58 ]. Также повышенная экспрессия miR-425-3p, наряду с miR-584-5p, была обнаружена в плазме крови пациентов с колоректальным раком, и в целом эта микроРНК связана с неблагоприятным прогнозом при раках различных этиологий [ 59 ].…”

“…Трижды негативный Cr МЖ (↓) Онкосупрессор [50] Cr ПЖ (↓) [51] АКР (↓) [52] Колоректальный Cr (↓) [53] Cr МЖ (↓) [54] Cr мочевого пузыря (↓) [55] miR-32-5p Cr ПЖ (↓) Онкосупрессор [56] Плоскоклеточный Cr полости рта (↑) Промотор канцерогенеза [57] miR-425-3p Cr протоков ПЖ (↑) Промотор канцерогенеза [58] Колоректальный Cr (↑) [59] miR-141-3p Колоректальный Cr (↑) Промотор канцерогенеза [60] Cr легкого [65] miR-501-3p…”

Noncoding RNAs: an emerging modulator of drug resistance in pancreatic cancer

“…Interestingly, a number of studies attempted to investigate the diagnostic value of circulating miRNAs in PC ( Previdi et al, 2017 ). Recently, a pilot study has proposed that an exosomal four miRNA biomarker panel, consisting of miR-93-5p, miR-339-3p, miR-425-5p, and miR-425-3p, may provide a promising avenue for PC screening ( Makler and Asghar, 2023 ). Although the diagnostic and prognostic potential of ncRNAs have shown the promising results, large and prospective validation studies should be implemented before they can enter clinical practice.…”

Study of the miRNA expression profile of cholesteatoma-derived exosomes and its clinical application

“…For instance, the exosomal miR-17-92a level in serum is correlated with the recurrence of human colorectal cancer [18]. Additionally, a set of miRNAs in plasma exosomes, including miR-93-5p, miR-339-3p, miR-425-5p, and miR-425-3p, was investigated as promising biomarkers for detecting pancreatic ductal adenocarcinoma [19]. Therefore, our research proceeded to identify key exosomal miRNAs that can serve as potential biomarkers for the preoperative diagnosis of cholesteatoma and for the early detection of recurrence in postoperative patients.…”